Ads
related to: clvs stock price
Search results
Clovis (CLVS) Stock Down 50% in the Past 6 Months: Here's Why
Zacks via Yahoo Finance· 1 year agoClovis Oncology, Inc.’s CLVS shares have plunged 49.6% in the past six months against the industry’s...
Down 67.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Clovis (CLVS)
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) has become technically an oversold stock now, which implies exhaustion of the heavy...
Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings...
Bet on 5 Top Stocks With Rising P/E
Zacks via Yahoo Finance· 1 year agoInvestors always look for stocks with low P/E ratios as the measure indicates undervaluation. This ratio is obtained by dividing a stock’s current market...
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the...
What Kind Of Shareholders Own Clovis Oncology, Inc. (NASDAQ:CLVS)?
Simply Wall St. via Yahoo Finance· 2 years agoIf you want to know who really controls Clovis Oncology, Inc. (NASDAQ:CLVS), then you'll have to...
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
Zacks via Yahoo Finance· 2 years agoClovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed...
Clovis (CLVS) Up 19.4% on Upbeat Data From Solid Tumor Study
Zacks via Yahoo Finance· 2 years agoClovis Oncology (CLVS) reports favorable data from a study, which supports the potential clinical...
7 Penny Stocks to Buy Before the Bull Market Returns
InvestorPlace via Yahoo Finance· 2 years agoIn recent weeks, the stock market has stabilized after June’s sell-off, but it may take time before bullishness makes a comeback. Plenty of uncertainty...
Why Clovis Oncology Zoomed 30% Higher Today
Motley Fool· 2 years agoCancer-focused biotech Clovis Oncology (NASDAQ: CLVS) was a stock on fire Monday. On Sunday, Clovis reported that Rubraca tested very well as a...
